End-of-study findings from the GIM2 trial indicate that adjuvant anthracyclines plus taxane chemotherapy for high-risk early breast cancer should be given in a dose-dense regimen and should not include fluorouracil.

Extending adjuvant aromatase inhibition to beyond 5 years of sequential therapy should not be recommended to all postmenopausal women with hormone receptor-positive early breast cancer, but some subgroups may benefit, research suggests.

Among people with endocrine-resistant, hormone receptor-positive, HER2-negative advanced breast cancer, sacituzumab govitecan is associated with significantly improved overall survival relative to standard of care, show data from TROPiCS-02.

Dalpiciclib given in combination with an aromatase inhibitor offers a novel first-line treatment option for patients with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer, say the DAWNA-2 investigators.

Adding the CD73 inhibitor oleclumab to durvalumab plus platinum-doublet chemotherapy does not improve the clinical benefit rate among women with treatment-naïve advanced triple-negative breast cancer, the SYNERGY investigators have found.

Updated findings from the MONARCH 3 trial show a nonsignificant overall survival gain with the addition of abemaciclib to a first-line nonsteroidal aromatase inhibitor in postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Hope Rugo outlines the latest results from the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor-positive, HER2-negative advanced breast cancer and discusses where the antibody–drug conjugate fits into the treatment paradigm.

medwireNews : The European School of Oncology (ESO) and the European Society of Medical Oncology (ESMO) have issued an update to their consensus recommendations for the management of breast cancer in young women.

The team concludes that “[t]he monitoring, diagnosis, and management of ILD/pneumonitis is an area of continuing improvement,” and refers clinicians to guidelines updated in 2019 on the dosing and supportive care required during T-DXd treatment. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group ESMO Open 2022; doi:10.1016/j.esmoop.2022.100554

The antibody–drug conjugate trastuzumab deruxtecan induces a high intracranial response rate among women with HER2-positive breast cancer and active brain metastases, TUXEDO-1 study findings indicate.

One dose of patritumab deruxtecan induces a clinically meaningful response in women with hormone receptor-positive, HER2-negative early breast cancer, show data from the SOLTI TOT-HER3 trial.

Exploratory analyses from the MONALEESA-3 trial after more than 5 years of follow-up show that first-line use of ribociclib alongside fulvestrant continues to offers a significant overall survival benefit versus fulvestrant alone in patients with hormone receptor-positive, HER2-negative advanced breast cancer.

The response to trastuzumab deruxtecan in patients with metastatic breast cancer differs significantly by tumoral levels of HER2 expression, indicate results from the DAISY trial.

Early results from the BEGONIA trial point to the potential of first-line treatment with datopotamab deruxtecan plus durvalumab in people with advanced triple-negative breast cancer.

medwireNews : ESMO has issued a Clinical Practice Guideline on using patient-reported outcome measures (PROMs) during the care of people with cancer.

Updated results from the OlympiA trial indicate that use of adjuvant olaparib significantly improves overall survival compared with placebo for patients with HER2-negative, early-stage breast cancer who have germline BRCA1/2 mutations.